



Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate


Supplementary Materials




Supplementary Figure S1: Aspirin counteracts the effect of IL-6 on c-Myc, p53 expression and E-cadherin expression. Densitometric analysis of c-Myc, p53 and E-cadherin protein expression in control and IL-6-stimulated cells treated with aspirin for 24 hours. (A) NCM460 and HepG2 cells treated with aspirin at a concentration of 0.1 mM. (B) NCM460, HepG2, MCF10A and MEF cells treated with aspirin at a concentration of 0.5 mM. (C) NCM460 and HepG2 cells treated with aspirin at a concentration of 1.5 mM. The histograms show the values (mean \pm s.d.) of three experiments. * $P < 0.05$; ** $P < 0.01$. n.s., not significant.




Supplementary Figure S2: Aspirin counteracts the effect of IL-6 on cell invasiveness. Invasion assay filters of NCM460 and HepG2 cells. Cells were exposed to IL-6 and/or to aspirin 0.5 mM for 24 hours. In both cell lines, aspirin counteracted the effect of IL-6 on the invasiveness potential.




Supplementary Figure S3: Aspirin increases the 45S rRNA amount in control and IL-6-stimulated cells. Real-time RT-PCR analysis of the 45S rRNA expression in control and IL-6-stimulated NCM460, HepG2, MCF10A and MEF cells, treated with aspirin for 24 hours. The histograms show the values (mean \pm s.d.) of three experiments. * $P < 0.05$; ** $P < 0.01$.




Supplementary Figure S4: : Aspirin counteracts the effect of IL-6 on 28S and 18S rRNA amount. NCM460 and HepG2 cells treated with 0.5 mM aspirin and/or IL-6 for 24 h. Total RNA was size-separated on 1% agarose gel and stained with ethidium bromide. Two bands corresponding to 28S and 18S rRNA are visible in each lane.




Supplementary Figure S5: c-MYC silencing and RPS6 mRNA expression in NCM460 cells. (A) Real-time RT-PCR evaluation of c-Myc mRNA expression and Western blot analysis of c-Myc protein expression in NCM460. The cells were interfered with scrambled (SCR) or c-Myc siRNA (MYC-) for 48 h. (B) Real-time PCR analysis of the RPS6 mRNA levels in NCM460 cells. The cells were interfered with scramble (SCR) or c-Myc siRNA (MYC-) for 48 h and then exposed to IL-6 for 24 hours. IL-6 greatly stimulated the RPS6 mRNA transcription; c-Myc interference caused a reduction in the RPS6 mRNA amount both in control and IL-6 stimulated cells. The histograms show the values (mean \pm s.d.) of three experiments. $**P < 0.01$.




Supplementary Figure S6: Efficiency of RPL11 silencing. (A) siRNA1: Real-time RT-PCR evaluation of RPL11 mRNA expression in NCM460 and HepG2 cells. The cells were interfered with scrambled (SCR) or RPL11 siRNA1 (L11-) for 48 h. (B) siRNA2: Real-time RT-PCR evaluation of RPL11 mRNA expression and Western blot analysis of RPL11 protein expression in NCM460 and HepG2 cells. The cells were interfered with scrambled (SCR) or RPL11 siRNA2 (L11-) for 48h. The histograms show the values (mean \pm s.d.) of three experiments.




Supplementary Figure S7: Cell cycle analysis. The NCM460 cell line was treated with different dosages of aspirin (0.5, 1, 1.5, 3 mM) for 24 h. Cells were collected and fixed in 70% ethanol at 4°C for 16 h. Fixed cells were then washed once with PBS, resuspended in 500 µl PBS containing 10 µg ml⁻¹ propidium iodide and 50 µg ml⁻¹ RNase and incubated for 30 min at room temperature. The cells were then centrifuged at 1200 rpm for 5 min, resuspended in 500 µl of PBS and analysed with Fluorescent-Activated Cell Sorter (BD FACSaria cell sorter, BD Biosciences, San Jose, CA, USA).



Supplementary Figure S8: Increasing aspirin concentrations induce a progressive reduction of the cell proliferation rate. Long-term effect (96 h) of aspirin treatment at the doses of 0.1, 0.3, 0.5, 1, 1.5 and 3 mM on the proliferation rate in NCM460 and HepG2 cells. O.D.: optical density. The IC₅₀, calculated at 24 h, was 1.52 mM for NCM460 cells and 1.53 mM for HepG2 cells.



Supplementary Figure S9: IL-6 silencing and p53 expression in HepG2 cells. Real-time RT-PCR evaluation of 45S rRNA expression, Western blot and densitometric analysis of p53 in control and IL-6-stimulated NCM460 and HepG2 cells treated with (A) 0,5 mM salicylate (SA) or (B) 1 mM mesalazine (5-ASA) for 24 h. Both drugs counteract the effect of IL-6 on p53 expression. Moreover, drugs increase the 45S rRNA and p53 expression in control and IL-6-stimulated cells. The histograms show the values (mean ± s.d.) of three experiments. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.



Supplementary Figure S10: IL-6 silencing and p53 expression in HepG2 cells. HepG2 cells were interfered with scramble (SCR) or IL-6 siRNA (IL-6-) for 48 h and then exposed to aspirin 0,5 mM for 24 hours. (A) Real-time RT-PCR evaluation of IL-6 mRNA and 45S rRNA expression in HepG2 cells. (B) Western blot analysis of p53 protein expression in HepG2 cells. Aspirin induced a p53 stabilization also in IL-6 silenced cells. The histograms show the values (mean \pm s.d.) of three experiments.

Supplementary Table S1: Real-time RT-PCR primer sequences

Human primer sequences:	
45S rRNA	FOR: 5'-GAACGGTGGTGTGTCGTT-3' REV: 5'-GCGTCTCGTCTCGTCTCACT-3'
c-Myc	FOR: 5'-CTGCGACGAGGAGGAGGACT-3' REV: 5'-GGCAGCAGCTCGAATTTCTT-3'
RPS6	FOR: 5'-TCTTGACCCATGGCCGTGTC-3' REV: 5'-GCGGCAAGGCACTGTAGTAT-3'
RPL11	FOR: 5'-TCCACTGCACAGTTCGAGGG-3' REV: 5'-AAACCTGGCCTACCCAGCAC-3'
RPS14	FOR: 5'-GCCTCGGACCTCAGGTGG-3' REV: 5'-GTAGGCGGTGATACCCAG-3'
IL-6	FOR: 5'-GAGAAAGGAGACATGTAACA-3' REV: 5'-GCGCAGAATGAGATGAGTTGT-3'
TP53	FOR: 5'-TAACAGTTCCTGCATGGGC-3' REV: 5'-AGGACAGGCACAAACACGC-3'
Mouse primer sequences:	
actin	FOR: 5'-AGAGGGAAATCGTGCGTGAC-3' REV: 5'-CAATAGTGATGACCTGGCCGT-3'
45S rRNA	FOR: 5'-CTCCTGTCTGTGGTGTCCAA-3' REV: 5'-TGATACGGGCAGACACAGAA-3'